User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.
A user's progress pictures showing the results of taking Fin (0.5 mg per day), Min (5 mg per day) and microneedling with Dr. Pen Ultima M8; another user asked when the regrowth was noticed, and commented on the hair appearing darker.
OP is unsure if their hair is improving or worsening despite using Topical Fin, Pyri, Keto Shampoo, TGel, Microneedling, and Tretinoin. A user suggests switching to oral Fin and Minoxidil.
Teenager with hair loss shares experience and encourages others to address their hair loss early. They use a stack of topical finasteride/minoxidil, derma stamp, and ketoconazole shampoo for treatment.
A 22-year-old experiencing hair loss and persistent scalp itchiness since age 16 has tried various treatments, including finasteride, ketoconazole shampoo, and dietary changes, with no success. Suggestions include consulting a knowledgeable dermatologist, considering seborrheic dermatitis, and trying different shampoos like Selsun Blue or those with selenium sulfide.
A 21-year-old male shares his 3-month progress using 0.5mg dutasteride daily, 5% topical minoxidil twice daily, and weekly microneedling, showing some temple recovery and seeking further improvement. Feedback suggests continued use and monitoring, with optimism for more regrowth over time.
Creatine may cause increased hair shedding due to androgen receptor sensitivity, despite limited evidence. The user is using dutasteride and minoxidil and seeks advice on whether shedding will stabilize, with suggestions including GHK-Cu and RU58841.
The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.